Major Depressive Disorder Clinical Trials in Maitland, Florida

4 studies are recruiting for major depressive disorder in Maitland, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Maitland, Florida
    Locations
    35 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963021 on ClinicalTrials.gov

  2. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

    Stage
    Phase 3
    Ages
    18 to 74
    Site
    K2 Medical Research (Maitland), Maitland, Florida
    Locations
    30 in total
    Run by
    Definium Therapeutics US, Inc.

    See if you can join NCT07592689 on ClinicalTrials.gov

  3. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Maitland, Florida
    Locations
    106 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06966401 on ClinicalTrials.gov

  4. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Maitland, Florida
    Locations
    18 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06786624 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.